Filippo de Marinis
Impact in
- Pulmonary and Respiratory Medicine top 0.01%
- Lung Cancer Treatments and Mutations
- Lung Cancer Diagnosis and Treatment
- Brain Metastases and Treatment
- Oncology top 0.05%
- Lung Cancer Research Studies
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
Papers in
-
- Lung Cancer Treatments and Mutations 307
- Lung Cancer Diagnosis and Treatment 93
- Gastric Cancer Management and Outcomes 20
- Oncology 227
- Lung Cancer Research Studies 108
- Cancer Immunotherapy and Biomarkers 64
- Colorectal Cancer Treatments and Studies 46
- Co-authors
- Joachim von Pawel (12 shared papers)Ulrich Gatzemeier (7 shared papers)Giorgio V. Scagliotti (26 shared papers)Keunchil Park (10 shared papers)Christian Manegold (6 shared papers)Antonio Passaro (84 shared papers)Tony S.K. Mok (29 shared papers)Jose R. Pereira (4 shared papers)
- Journals
- Annals of Oncology (69 papers)Lung Cancer (53 papers)Journal of Thoracic Oncology (42 papers)Journal of Clinical Oncology (24 papers)Clinical Lung Cancer (22 papers)
- Partner nations
- ItalyUnited StatesSpain
In The Last Decade
Filippo de Marinis
450 papers receiving 35.5k citations
Filippo de Marinis's Hit Papers
Peers
Comparison fields: 5 of 156
- Pulmonary and Respiratory Medicine 22.0k
- Oncology 17.7k
- Cancer Research 4.0k
- Immunology 1.6k
- Molecular Biology 5.3k
Countries citing papers authored by Filippo de Marinis
This map shows the geographic impact of Filippo de Marinis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Filippo de Marinis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Filippo de Marinis more than expected).
Fields of papers citing papers by Filippo de Marinis
This network shows the impact of papers produced by Filippo de Marinis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Filippo de Marinis. The network helps show where Filippo de Marinis may publish in the future.
Co-authors
The 25 scholars most cited alongside Filippo de Marinis, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 464 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Hit paper breakdown → | 2012 | 4725 |
| 2 | Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial Hit paper breakdown → | 2016 | 3949 |
| 3 | Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With Advanced-Stage Non–Small-Cell Lung Cancer Hit paper breakdown → | 2008 | 2714 |
| 4 | Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy Hit paper breakdown → | 2004 | 2068 |
| 5 | Osimertinib in Resected EGFR -Mutated Non–Small-Cell Lung Cancer Hit paper breakdown → | 2020 | 1288 |
| 6 | Atezolizumab for First-Line Treatment of PD-L1–Selected Patients with NSCLC Hit paper breakdown → | 2020 | 1271 |
| 7 | Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial Hit paper breakdown → | 2009 | 1126 |
| 8 | First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer Hit paper breakdown → | 2020 | 804 |
| 9 | Phase III Randomized Trial Comparing Three Platinum-Based Doublets in Advanced Non–Small-Cell Lung Cancer Hit paper breakdown → | 2002 | 778 |
| 10 | Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer Hit paper breakdown → | 2020 | 732 |
| 11 | PARAMOUNT: Final Overall Survival Results of the Phase III Study of Maintenance Pemetrexed Versus Placebo Immediately After Induction Treatment With Pemetrexed Plus Cisplatin for Advanced Nonsquamous Non–Small-Cell Lung Cancer Hit paper breakdown → | 2013 | 505 |
| 12 | Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial Hit paper breakdown → | 2012 | 493 |
| 13 | EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study Hit paper breakdown → | 2011 | 489 |
| 14 | Overall Survival with Osimertinib in Resected EGFR -Mutated NSCLC Hit paper breakdown → | 2023 | 402 |
| 15 | 2010 | 377 | |
| 16 | Updated Efficacy and Safety Data and Impact of the EML4-ALK Fusion Variant on the Efficacy of Alectinib in Untreated ALK-Positive Advanced Non–Small Cell Lung Cancer in the Global Phase III ALEX Study Hit paper breakdown → | 2019 | 369 |
| 17 | 2018 | 360 | |
| 18 | 1999 | 318 | |
| 19 | Multicenter Phase II Study of Whole-Body and Intracranial Activity With Ceritinib in Patients With ALK -Rearranged Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy and Crizotinib: Results From ASCEND-2 Hit paper breakdown → | 2016 | 312 |
| 20 | 1997 | 277 |
About Filippo de Marinis
Filippo de Marinis is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Cancer Research, Radiology, Nuclear Medicine and Imaging and Molecular Biology, having authored 464 papers that have together received 36.5k indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (307 papers), Lung Cancer Research Studies (108 papers), Lung Cancer Diagnosis and Treatment (93 papers), Cancer Immunotherapy and Biomarkers (64 papers), Colorectal Cancer Treatments and Studies (46 papers), Cancer Genomics and Diagnostics (37 papers), Cancer therapeutics and mechanisms (25 papers) and Gastric Cancer Management and Outcomes (20 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (22.0k citations), Oncology (17.7k citations), Cancer Research (4.0k citations), Immunology (1.6k citations) and Molecular Biology (5.3k citations). Filippo de Marinis has collaborated with scholars based in Italy, United States and Spain. Frequent co-authors include Joachim von Pawel, Ulrich Gatzemeier, Giorgio V. Scagliotti, Keunchil Park, Christian Manegold, Antonio Passaro, Tony S.K. Mok, Jose R. Pereira, Cesare Gridelli and Johan Vansteenkiste. Their work appears in journals such as Annals of Oncology, Lung Cancer, Journal of Thoracic Oncology, Journal of Clinical Oncology and Clinical Lung Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.